Eight Allergy Companies to Watch in 2026

Why It Matters

These advances signal a rapid commercialization pipeline that could reshape allergy care and generate sizable new revenue streams, while drawing heavyweight pharmaceutical investment into the space.

Key Takeaways

• Allergy Therapeutics' Grassmuno approved in Germany, short‑course immunotherapy.
• Aravax readies PVX108 for phase 3 after $42 M Series B.
• DBV’s VIASKIN peanut patch met phase 3 primary endpoint, BLA planned.
• IgGenix completed phase 1 of IGNX001, a peanut‑specific IgG4 antibody.
• Allergy market to hit $4.9 B by 2033, growing 10.4% CAGR.

Pulse Analysis

Allergy treatment is undergoing a paradigm shift as biotech firms replace antihistamines and epinephrine pens with disease‑modifying solutions. Immunotherapy, monoclonal antibodies, and novel vaccine platforms promise long‑term desensitisation, addressing the rising prevalence of allergic disorders driven by urbanisation and climate change. This transition is underpinned by robust market dynamics: the allergy immunotherapy sector, valued at $1.8 billion in 2023, is forecast to more than double to $4.9 billion by 2033, reflecting a 10.4% compound annual growth rate. Investors are taking note, with major pharmaceutical players allocating billions to acquire next‑generation candidates.

Among the innovators, eight companies stand out. Allergy Therapeutics secured German marketing authorization for Grassmuno, a six‑injection grass‑pollen vaccine that shortens treatment timelines. Aravax, fresh from a $42 million Series B, is positioning its peptide‑based PVX108 for a phase 3 trial, while DBV Technologies announced that its VIASKIN peanut patch achieved a 46.6% responder rate in a phase 3 pediatric study, paving the way for a U.S. Biologics License Application. Parallel advances include IgGenix’s phase 1 completion of IGNX001, a high‑affinity IgG4 antibody, Inimmune’s phase 2 start for INI‑2004, Intrommune’s safe phase 1 data for the toothpaste‑based INT302, Mabylon’s launch of a phase 1a/b trial for the trispecific MY006, and Stallergenes Greer’s China partnership to expand Actair.

The convergence of clinical breakthroughs and strategic capital inflows is reshaping the competitive landscape. Big‑pharma deals—GSK’s $2.2 billion acquisition of Rapt Therapeutics and Novartis’s up‑to‑$2 billion deal for Excellergy—underscore the sector’s attractiveness and foreshadow potential consolidation. As these pipelines advance toward regulatory approval, the allergy market could see a wave of new, reimbursable products, offering patients durable protection and investors diversified growth opportunities. Companies that successfully navigate late‑stage trials and secure global launches are poised to capture significant market share in a rapidly expanding therapeutic arena.